Exact Diagnostics, a Bio-Rad Laboratories Company, Announces the Launch of EDX Respiratory Panel Control for Use with Molecular-Based Clinical Assays
HERCULES, Calif. – Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Exact Diagnostics, a company that Bio-Rad acquired in the third quarter of 2019, has launched EDX RP Positive Run Control, an unassayed external quality control intended to monitor the performance of clinical respiratory assays.
Routine use of EDX RP Positive Run Control allows laboratories to meet their individualized quality control goals, including evaluation of reagent lot changes and new shipments. In addition it monitors multiple identical devices and provides an assessment of different personnel and locations.
The EDX RP Positive Run Control contains 22 respiratory analytes that are internally value-assigned using Bio-Rad’s Digital Droplet PCR technology. The new multiplex control is a combination of whole, intact virus and bacteria samples that have been heated or chemically inactivated, as well as synthetic RNA transcripts. The control is designed to test the entire process of a molecular assay including extraction, detection, and amplification. EDX RP Positive Run Control is the first multi-analyte control to target 22 analytes in a single vial, which can save laboratories time and space on their instruments.
Exact Diagnostics is a leader in developing and manufacturing a broad range of innovative molecular diagnostics products designed to meet the quality control needs of clinical labs and assay manufacturers. By providing quality products and services to clinical laboratories and manufacturers, Exact Diagnostics enhances patient care by helping to ensure the validity of diagnostic and screening tests results. For more information on this product and other Exact Diagnostic products, please visit exactdiagnostics.com.
BIO-RAD and DROPLET DIGITAL PCR are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology, pharmaceutical, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 8,100 employees worldwide. Bio-Rad had revenues exceeding $2.2 billion in 2018. For more information, please visit bio-rad.com.
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our expectations regarding our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “plan”, “believe,” “expect,” “anticipate,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
Bio-Rad Laboratories, Inc.
Tina Cuccia, Corporate Communications